AtriCure Completes Patient Enrollment for aMAZE Trial

AtriCure is rolling into the new year with some significant milestones that help reinforce the presence it has built in the cardiovascular space. The company has been at the forefront of the space in the past – by receiving significant investor attention for its work in atrial fibrillation (Afib) and left atrial appendage (LAA) management. Back in 2018, AtriCure was featured prominently in a report detailing the 25 Most Attractive Medtech Companies on the M&A Radar from Needham & Co analyst Mike Matson. Now just a few short days into the new year, the Mason, OH-based company showed why it has always been well-recognized in the medtech industry by reaching two important milestones. The first milestone is the completion of enrollment for the 600-patient aMAZE Clinical Trial and FDA approval of continued access protocol (CAP). The trial is evaluating the Lariat Suture Delivery Device for LAA exclusion adjunctive to Pulmonary Vein Isolation (PVI) catheter ablation for the treatment of persistent and long-standing persistent Afib. Lariat uses a percutaneous suture-based approach to close the left atrial appendage. Atricure inherited the device when it acquired Redwood City, CA-based SentreHeart for $300 million (Editor’s note this figure includes potential milestone payments) in August of 2019. In AtriCure’s most recent earnings call, company president and CEO Mike Carrell spoke about the importance of the acquisition. ...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Business Source Type: news